Brief: Biomea Fusion Announces Phase 1 Results For Bmf-650, Its Investigational Next-Generation Oral Small Molecule Glp-1 Receptor Agonist

Biomea Fusion

13/10/2026 21:12

Oct 13 (Reuters) - Biomea Fusion, Inc. BMEA.O:
BIOMEA FUSION ANNOUNCES PHASE 1 RESULTS FOR BMF-650, ITS INVESTIGATIONAL NEXT-GENERATION ORAL SMALL MOLECULE GLP-1 RECEPTOR AGONIST
BIOMEA FUSION - NO SEVERE OR SERIOUS ADVERSE EVENTS REPORTED IN BMF-650 PHASE 1 MAD PARTICIPANTS
BIOMEA FUSION - ALL ADVERSE EVENTS IN FIVE MAD COHORTS WERE MILD OR MODERATE
BIOMEA FUSION - NO INCREASED ALT OR AST ADVERSE EVENTS REPORTED IN BMF-650 PHASE 1 STUDY
BIOMEA FUSION - RAPID ONE-STEP TITRATION TO 400 MG QD WELL TOLERATED IN COHORT 5
BIOMEA FUSION - PHASE 1 BMF-650 SHOWS 1.5%-3.2% MEAN WEIGHT REDUCTION AT DAY 29 IN COHORTS 1-4
BIOMEA FUSION, INC.: MEAN WEIGHT REDUCTION RANGED FROM 1.5% TO 3.2% AT DAY 29 ACROSS COHORTS 1-4, COMPARED WITH 0.1% FOR POOLED PLACEBO
BIOMEA FUSION - COHORT 5 SHOWS 6.1% MEAN WEIGHT REDUCTION AT DAY 29, 1.55 KG PER WEEK
BIOMEA FUSION: IN AN ADDITIONAL FIFTH COHORT CONDUCTED UNDER CONFINEMENT, AT DAY 29, MEAN WEIGHT REDUCTION AVERAGED ABOUT 1.55 KG PER WEEK
BIOMEA FUSION: CONFINEMENT APPEARS TO HAVE AFFECTED EATING BEHAVIOR FOR COHORT 5 PARTICIPANTS, BELIEVE ITS RESULTS SHOULD BE INTERPRETED SEPARATELY
Source text: ID:nGNX8WMc94
Further company coverage: BMEA.O

 ((Reuters.Briefs@thomsonreuters.com;))